BAFF mediates splenic B cell response and antibody production in experimental chagas disease

PLoS Neglected Tropical Diseases

Volumn 4, Issue 5, 2010, Pages

  Bermejo, Daniela A ^a   Amezcua Vesely, Maria Carolina ^a   Montes, Carolina L ^a   Merino, María C ^a   Gehrau, Ricardo C ^a   Cejas, Hugo ^a   Acosta Rodríguez, Eva V ^a   Gruppi, Adriana ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTOZOON ANTIBODY; TNFSF13B PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CHAGAS DISEASE; CONTROLLED STUDY; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PARASITEMIA; PARASITISM; PROTEIN FUNCTION; SPLEEN LYMPHOCYTE; TRYPANOSOMA CRUZI; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DISEASE MODEL; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM; SPLEEN;

ANIMALS; ANTIBODIES, PROTOZOAN; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CHAGAS DISEASE; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; MICE, INBRED BALB C; SPLEEN; TRYPANOSOMA CRUZI;

EID: 77955289512     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000679     Document Type: Article

References (72)

1. Zuniga E, Motran CC, Montes CL, Yagita H, Gruppi A (2002) Trypanosoma cruzi infection selectively renders parasite-specific IgG+ B lymphocytes susceptible to Fas/Fas ligand-mediated fratricide. J Immunol 168: 3965-3973.
2. Zuniga E, Acosta-Rodriguez E, Merino MC, Montes C, Gruppi A (2005) Depletion of immature B cells during Trypanosoma cruzi infection: involvement of myeloid cells and the cyclooxygenase pathway. Eur J Immunol 35: 1849-1858.
3. Minoprio P, Bandeira A, Pereira P, Mota ST, Coutinho A (1989) Preferential expansion of Ly-1 B and CD4- CD8- T cells in the polyclonal lymphocyte responses to murine T. cruzi infection. Int Immunol 1: 176-184.
4. Ortiz-Ortiz L, Parks DE, Rodriguez M, Weigle WO (1980) Polyclonal B lymphocyte activation during Trypanosoma cruzi infection. J Immunol 124: 121-126.
5. D'Imperio Lima MR, Joskowicz M, Coutinho A, Kipnis T, Eisen H (1985) Very large and isotypically atypical polyclonal plaque-forming cell responses in mice infected with Trypanosoma cruzi. Eur J Immunol 15: 201-203.
6. D'Imperio Lima MR, Eisen H, Minoprio P, Joskowicz M, Coutinho A (1986) Persistence of polyclonal B cell activation with undetectable parasitemia in late stages of experimental Chagas' disease. J Immunol 137: 353-356.
7. Schmunis GA, Szarfman A, Coarasa L, Vainstok C (1978) Immunoglobulin concentration in treated human acute Chagas disease. A follow-up study. Am J Trop Med Hyg 27: 473-477.
8. Minoprio P, Burlen O, Pereira P, Guilbert B, Andrade L, et al. (1988) Most B cells in acute Trypanosoma cruzi infection lack parasite specificity. Scand J Immunol 28: 553-561.
9. Minoprio P, Itohara S, Heusser C, Tonegawa S, Coutinho A (1989) Immunobiology of murine T. cruzi infection: the predominance of parasitenonspecific responses and the activation of TCRI T cells. Immunol Rev 112: 183-207.
10. Khoury EL, Ritacco V, Cossio PM, Laguens RP, Szarfman A, et al. (1979) Circulating antibodies to peripheral nerve in American trypanosomiasis (Chagas' disease). Clin Exp Immunol 36: 8-15.
11. Leon JS, Daniels MD, Toriello KM, Wang K, Engman DM (2004) A cardiac myosin-specific autoimmune response is induced by immunization with Trypanosoma cruzi proteins. Infect Immun 72: 3410-3417.
12. Lanzavecchia A, Sallusto F (2007) Toll-like receptors and innate immunity in Bcell activation and antibody responses. Curr Opin Immunol 19: 268-274.
13. Montes CL, Vottero-Cima E, Gruppi A (1996) Trypanosoma cruzi cytosolic alkaline antigens (FI) induce polyclonal activation in murine normal B cells. Scand J Immunol 44: 93-100.
14. Minoprio P (2001) Parasite polyclonal activators: new targets for vaccination approaches? Int J Parasitol 31: 588-591.
15. Minoprio P, Eisen H, Joskowicz M, Pereira P, Coutinho A (1987) Suppression of polyclonal antibody production in Trypanosoma cruzi-infected mice by treatment with anti-L3T4 antibodies. J Immunol 139: 545-550.
16. Gao W, Wortis HH, Pereira MA (2002) The Trypanosoma cruzi trans-sialidase is a T cell-independent B cell mitogen and an inducer of non-specific Ig secretion. Int Immunol 14: 299-308.
17. Montes CL, Acosta-Rodriguez EV, Mucci J, Zuniga EI, Campetella O, et al. (2006) A Trypanosoma cruzi antigen signals CD11b+ cells to secrete cytokines that promote polyclonal B cell proliferation and differentiation into antibodysecreting cells. Eur J Immunol 36: 1474-1485.
18. Reina-San-Martin B, Degrave W, Rougeot C, Cosson A, Chamond N, et al. (2000) A B-cell mitogen from a pathogenic trypanosome is a eukaryotic proline racemase. Nat Med 6: 890-897.
19. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, et al. (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285: 260-263.
20. Schneider P, Mackay F, Steiner V, Hofmann K, Bodmer JL, et al. (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189: 1747-1756.
21. Batten M, Groom J, Cachero TG, Qian F, Schneider P, et al. (2000) BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 192: 1453-1466.
22. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, et al. (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190: 1697-1710.
23. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, et al. (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404: 995-999.
24. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, et al. (2001) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166: 6-10.
25. Zuniga E, Motran C, Montes CL, Diaz FL, Bocco JL, et al. (2000) Trypanosoma cruzi-induced immunosuppression: B cells undergo spontaneous apoptosis and lipopolysaccharide (LPS) arrests their proliferation during acute infection. Clin Exp Immunol 119: 507-515.
26. Lin WY, Gong Q, Seshasayee D, Lin Z, Ou Q, et al. (2007) Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood 110: 3959-3967.
27. Genestier L, Taillardet M, Mondiere P, Gheit H, Bella C, et al. (2007) TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol 178: 7779-7786.
28. Tezuka H, Abe Y, Iwata M, Takeuchi H, Ishikawa H, et al. (2007) Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells. Nature 448: 929-933.
29. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
30. Laderach D, Cerban F, Motran C, Vottero de CE, Gea S (1996) Trypanosoma cruzi: the major cysteinyl proteinase (cruzipain) is a relevant immunogen of parasite acidic antigens (FIII). Int J Parasitol 26: 1249-1254.
31. Zuniga E, Montes C, Barbieri G, Gruppi A (1999) Antibodies against Trypanosoma cruzi alkaline antigens are elicited in sera from acute but not chronic human chagasic patients. Clin Immunol 93: 81-89.
32. Acosta Rodriguez EV, Zuniga EI, Montes CL, Merino MC, Bermejo DA, et al. (2007) Trypanosoma cruzi infection beats the B-cell compartment favouring parasite establishment: can we strike first? Scand J Immunol 66: 137-142.
33. de Meis J, Morrot A, Farias-de-Oliveira DA, Villa-Verde DM, Savino W (2009) Differential regional immune response in Chagas disease. PLoS Negl Trop Dis 3(7): e417.
34. Merino M, Montes C, Acosta-Rodriguez E, Bermejo D, Amezcua-Vesely M, et al. (2009) Peritoneum from Trypanosoma cruzi infected mice is a homing site of Syndecan-1neg plasma cells which mainly provide non-parasite specific antibodies. International Immunology, In Press.
35. Gazzinelli R, Galvao LM, Dias JC, Gazzinelli G, Brener Z (1988) Anti-laminin and specific antibodies in acute Chagas disease. Trans R Soc Trop Med Hyg 82: 574-576.
36. Spinella S, Liegeard P, Hontebeyrie-Joskowicz M (1992) Trypanosoma cruzi: predominance of IgG2a in nonspecific humoral response during experimental Chagas' disease. Exp Parasitol 74: 46-56.
37. Milei J, Sanchez J, Storino R, Yu ZX, Denduchis B, et al. (1993) Antobodies to laminin and immunohistochemical localization of laminin in chronic chagasic cardiomyopathy: a review. Mol Cell Biochem 129(2): 161-170.
38. Mackay F, Groom JR, Tangye SG (2007) An important role for B-cell activation factor and B cells in the pathogenesis of Sjogren's syndrome. Curr Opin Rheumatol 19: 406-413.
39. He B, Qiao X, Klasse PJ, Chiu A, Chadburn A, et al. (2006) HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 176: 3931-3941.
40. Tarantino G, Marco VD, Petta S, Almasio PL, Barbaria F, et al. (2009) Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection. J Viral Hepat 16: 397-405.
41. Bogdan C, Rollinghoff M (1999) How do protozoan parasites survive inside macrophages? Parasitol Today 15: 22-28.
42. Van OL, Vanderheyde N, Verhasselt V, Ismaili J, De VL, et al. (1999) Trypanosoma cruzi infects human dendritic cells and prevents their maturation: inhibition of cytokines, HLA-DR, and costimulatory molecules. Infect Immun 67: 4033-4040.
43. Mackay F, Schneider P, Rennert P, Browning J (2003) BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21: 231-264.
44. Scapini P, Nardelli B, Nadali G, Calzetti F, Pizzolo G, et al. (2003) G-CSFstimulated neutrophils are a prominent source of functional BLyS. J Exp Med 197: 297-302.
45. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, et al. (2004) Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 199: 1631-1640.
46. Abrahamsohn IA (1998) Cytokines in innate and acquired immunity to Trypanosoma cruzi infection. Braz J Med Biol Res 31: 117-121.
47. Antunez MI, Cardoni RL (2001) Early IFN-gamma production is related to the presence of interleukin (IL)-18 and the absence of IL-13 in experimental Trypanosoma cruzi infections. Immunol Lett 79: 189-196.
48. Cuna WR, Encina JL, Cuna CR (2000) Interferon- or interleukin-10 production is induced by related Trypanosoma cruzi antigens. J Parasitol 86: 295-299.
49. Corral RS, Petray PB (2000) CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi. Vaccine 19: 234-242.
50. Gazzinelli RT, Denkers EY (2006) Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nat Rev Immunol 6: 895-906.
51. Meyer-Bahlburg A, Andrews SF, Yu KO, Porcelli SA, Rawlings DJ (2008) Characterization of a late transitional B cell population highly sensitive to BAFFmediated homeostatic proliferation. J Exp Med 205: 155-168.
52. Rauch M, Tussiwand R, Bosco N, Rolink AG (2009) Crucial role for BAFFBAFF- R signaling in the survival and maintenance of mature B cells. PLoS One 4(5): e5456.
53. Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9: 491-502.
54. Scholz JL, Crowley JE, Tomayko MM, Steinel N, O'Neill PJ, et al. (2008) BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci U S A 105: 15517-15522.
55. Golgher D, Gazzinelli RT (2004) Innate and acquired immunity in the pathogenesis of Chagas disease. Autoimmunity 37: 399-409.
56. Kierszenbaum F (2003) Views on the autoimmunity hypothesis for Chagas disease pathogenesis. FEMS Immunol Med Microbiol 37: 1-11.
57. Tarleton RL (2003) Chagas disease: a role for autoimmunity? Trends Parasitol 19: 447-451.
58. Malkiel S, Kuan AP, Diamond B (1996) Autoimmunity in heart disease: mechanisms and genetic susceptibility. Mol Med Today 2: 336-342.
59. Dighiero G, Rose NR (1999) Critical self-epitopes are key to the understanding of self-tolerance and autoimmunity. Immunol Today 20: 423-428.
60. Talvani A, Ribeiro CS, Aliberti JC, Michailowsky V, Santos PV, et al. (2000) Kinetics of cytokine gene expression in experimental chagasic cardiomyopathy: tissue parasitism and endogenous IFN-gamma as important determinants of chemokine mRNA expression during infection with Trypanosoma cruzi. Microbes Infect 2: 851-866.
61. Mackay F, Browning JL (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2: 465-475.
62. Ramanujam M, Davidson A (2004) The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Res Ther 6: 197-202.
63. Sutherland AP, Mackay F, Mackay CR (2006) Targeting BAFF: immunomodulation for autoimmune diseases and lymphomas. Pharmacol Ther 112: 774-786.
64. Zekavat G, Rostami SY, Badkerhanian A, Parsons RF, Koeberlein B, et al. (2008) In vivo BLyS/BAFF neutralization ameliorates islet-directed autoimmunity in nonobese diabetic mice. J Immunol 181: 8133-8144.
65. Fletcher CA, Sutherland AP, Groom JR, Batten ML, Ng LG, et al. (2006) Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells. Eur J Immunol 36: 2504-2514.
66. Jacob CO, Pricop L, Putterman C, Koss MN, Liu Y, et al. (2006) Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupusprone New Zealand mixed 2328 mice deficient in BAFF. J Immunol 177: 2671-2680.
67. Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, et al. (2005) BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 52: 2080-2091.
68. Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, et al. (2002) BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 17: 515-524.
69. Herlands RA, William J, Hershberg U, Shlomchik MJ (2007) Anti-chromatin antibodies drive in vivo antigen-specific activation and somatic hypermutation of rheumatoid factor B cells at extrafollicular sites. Eur J Immunol 37: 3339-3351.
70. Hsu MC, Toellner KM, Vinuesa CG, Maclennan IC (2006) B cell clones that sustain long-term plasmablast growth in T-independent extrafollicular antibody responses. Proc Natl Acad Sci U S A 103: 5905-5910.
71. Oliver AM, Martin F, Gartland GL, Carter RH, Kearney JF (1997) Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. Eur J Immunol 27: 2366-2374.
72. Cardillo F, Postol E, Nihei J, Aroeira LS, Nomizo A, et al. (2007) B cells modulate T cells so as to favour T helper type 1 and CD8+ T-cell responses in the acute phase of Trypanosoma cruzi infection. Immunology 122: 584-595.